Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100

Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100

We have previously demonstrated the immunogenicity of VGX-3100, a multicomponent DNA immunotherapy for the treatment of Human Papillomavirus (HPV)16/18-positive CIN2/3 in a phase 1 clinical trial. Here, we report on the ability to boost immune responses with an additional dose of VGX-3100. Patients...

Full description

Bibliographic Details
Main Authors: Matthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, Xuefei Shen, Dinah Amante, Lindsay Sakata, Lamar Parker, Jian Yan, Jean Boyer, Christian Roh, Laurent Humeau, Amir S Khan, Kate Broderick, Kathleen Marcozzi-Pierce, Mary Giffear, Jessica Lee, Cornelia L Trimble, J Joseph Kim, Niranjan Y Sardesai, David B Weiner, Mark L Bagarazzi
Format: Article
Language:English
Published: Elsevier 2016-01-01
Series:Molecular Therapy: Oncolytics
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770516300626

Internet

http://www.sciencedirect.com/science/article/pii/S2372770516300626

Similar Items